Teva Said to Pay $250 Million to End Propofol Lawsuits

Teva Pharmaceutical Industries Ltd. will pay more than $250 million to settle more than 80 lawsuits alleging the drugmaker sold the anesthetic Propofol in a way that led colonoscopy patients to develop hepatitis C, people familiar with the accords said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.